A citation-based method for searching scientific literature

Florence Lorget, Nabil Kaci, Jeff Peng, Catherine Benoist-Lasselin, Emilie Mugniery, Todd Oppeneer, Dan J Wendt, Sean M Bell, Sherry Bullens, Stuart Bunting, Laurie S Tsuruda, Charles A O'Neill, Federico Di Rocco, Arnold Munnich, Laurence Legeai-Mallet. Am J Hum Genet 2012
Times Cited: 101







List of co-cited articles
1132 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Overexpression of CNP in chondrocytes rescues achondroplasia through a MAPK-dependent pathway.
Akihiro Yasoda, Yasato Komatsu, Hideki Chusho, Takashi Miyazawa, Ami Ozasa, Masako Miura, Tatsuya Kurihara, Tomohiro Rogi, Shoji Tanaka, Michio Suda,[...]. Nat Med 2004
261
47

Mutations in the transmembrane domain of FGFR3 cause the most common genetic form of dwarfism, achondroplasia.
R Shiang, L M Thompson, Y Z Zhu, D M Church, T J Fielder, M Bocian, S T Winokur, J J Wasmuth. Cell 1994
914
41

Dwarfism and early death in mice lacking C-type natriuretic peptide.
H Chusho, N Tamura, Y Ogawa, A Yasoda, M Suda, T Miyazawa, K Nakamura, K Nakao, T Kurihara, Y Komatsu,[...]. Proc Natl Acad Sci U S A 2001
327
40

Systemic administration of C-type natriuretic peptide as a novel therapeutic strategy for skeletal dysplasias.
Akihiro Yasoda, Hidetomo Kitamura, Toshihito Fujii, Eri Kondo, Naoaki Murao, Masako Miura, Naotetsu Kanamoto, Yasato Komatsu, Hiroshi Arai, Kazuwa Nakao. Endocrinology 2009
78
47

Neutral endopeptidase-resistant C-type natriuretic peptide variant represents a new therapeutic approach for treatment of fibroblast growth factor receptor 3-related dwarfism.
Daniel J Wendt, Melita Dvorak-Ewell, Sherry Bullens, Florence Lorget, Sean M Bell, Jeff Peng, Sianna Castillo, Mika Aoyagi-Scharber, Charles A O'Neill, Pavel Krejci,[...]. J Pharmacol Exp Ther 2015
55
63

Mutations in the gene encoding fibroblast growth factor receptor-3 in achondroplasia.
F Rousseau, J Bonaventure, L Legeai-Mallet, A Pelet, J M Rozet, P Maroteaux, M Le Merrer, A Munnich. Nature 1994
649
33


Achondroplasia.
William A Horton, Judith G Hall, Jacqueline T Hecht. Lancet 2007
266
32

Mutations in the transmembrane natriuretic peptide receptor NPR-B impair skeletal growth and cause acromesomelic dysplasia, type Maroteaux.
Cynthia F Bartels, Hulya Bükülmez, Pius Padayatti, David K Rhee, Conny van Ravenswaaij-Arts, Richard M Pauli, Stefan Mundlos, David Chitayat, Ling-Yu Shih, Lihadh I Al-Gazali,[...]. Am J Hum Genet 2004
226
30

Statin treatment rescues FGFR3 skeletal dysplasia phenotypes.
Akihiro Yamashita, Miho Morioka, Hiromi Kishi, Takeshi Kimura, Yasuhito Yahara, Minoru Okada, Kaori Fujita, Hideaki Sawai, Shiro Ikegawa, Noriyuki Tsumaki. Nature 2014
120
28

Interaction of fibroblast growth factor and C-natriuretic peptide signaling in regulation of chondrocyte proliferation and extracellular matrix homeostasis.
Pavel Krejci, Bernard Masri, Vincent Fontaine, Pertchoui B Mekikian, Maryann Weis, Herve Prats, William R Wilcox. J Cell Sci 2005
104
27

Postnatal soluble FGFR3 therapy rescues achondroplasia symptoms and restores bone growth in mice.
Stéphanie Garcia, Béatrice Dirat, Thomas Tognacci, Nathalie Rochet, Xavier Mouska, Stéphanie Bonnafous, Stéphanie Patouraux, Albert Tran, Philippe Gual, Yannick Le Marchand-Brustel,[...]. Sci Transl Med 2013
54
50

Fibroblast growth factor receptor 3 is a negative regulator of bone growth.
C Deng, A Wynshaw-Boris, F Zhou, A Kuo, P Leder. Cell 1996
832
23

Overexpression of the C-type natriuretic peptide (CNP) is associated with overgrowth and bone anomalies in an individual with balanced t(2;7) translocation.
Renata Bocciardi, Roberto Giorda, Jens Buttgereit, Stefania Gimelli, Maria Teresa Divizia, Silvana Beri, Silvio Garofalo, Sara Tavella, Margherita Lerone, Orsetta Zuffardi,[...]. Hum Mutat 2007
90
25

Constitutive activation of MEK1 in chondrocytes causes Stat1-independent achondroplasia-like dwarfism and rescues the Fgfr3-deficient mouse phenotype.
Shunichi Murakami, Gener Balmes, Sandra McKinney, Zhaoping Zhang, David Givol, Benoit de Crombrugghe. Genes Dev 2004
198
19

Critical roles of the guanylyl cyclase B receptor in endochondral ossification and development of female reproductive organs.
Naohisa Tamura, Lynda K Doolittle, Robert E Hammer, John M Shelton, James A Richardson, David L Garbers. Proc Natl Acad Sci U S A 2004
200
19


An overgrowth disorder associated with excessive production of cGMP due to a gain-of-function mutation of the natriuretic peptide receptor 2 gene.
Kohji Miura, Noriyuki Namba, Makoto Fujiwara, Yasuhisa Ohata, Hidekazu Ishida, Taichi Kitaoka, Takuo Kubota, Haruhiko Hirai, Chikahisa Higuchi, Noriyuki Tsumaki,[...]. PLoS One 2012
71
25

Intermittent PTH (1-34) injection rescues the retarded skeletal development and postnatal lethality of mice mimicking human achondroplasia and thanatophoric dysplasia.
Yangli Xie, Nan Su, Min Jin, Huabing Qi, Junbao Yang, Can Li, Xiaolan Du, Fengtao Luo, Bo Chen, Yue Shen,[...]. Hum Mol Genet 2012
32
56

FGFR3 promotes synchondrosis closure and fusion of ossification centers through the MAPK pathway.
Takehiko Matsushita, William R Wilcox, Yuk Yu Chan, Aya Kawanami, Hülya Bükülmez, Gener Balmes, Pavel Krejci, Pertchoui B Mekikian, Kazuyuki Otani, Isakichi Yamaura,[...]. Hum Mol Genet 2009
72
25

Meclozine promotes longitudinal skeletal growth in transgenic mice with achondroplasia carrying a gain-of-function mutation in the FGFR3 gene.
Masaki Matsushita, Satoru Hasegawa, Hiroshi Kitoh, Kensaku Mori, Bisei Ohkawara, Akihiro Yasoda, Akio Masuda, Naoki Ishiguro, Kinji Ohno. Endocrinology 2015
28
64


A cluster of translocation breakpoints in 2q37 is associated with overexpression of NPPC in patients with a similar overgrowth phenotype.
Anne Moncla, Chantal Missirian, Pierre Cacciagli, Eve Balzamo, Laurence Legeai-Mallet, Jean-Luc Jouve, Brigitte Chabrol, Martine Le Merrer, Ghislaine Plessis, Laurent Villard,[...]. Hum Mutat 2007
61
27

Meclozine facilitates proliferation and differentiation of chondrocytes by attenuating abnormally activated FGFR3 signaling in achondroplasia.
Masaki Matsushita, Hiroshi Kitoh, Bisei Ohkawara, Kenichi Mishima, Hiroshi Kaneko, Mikako Ito, Akio Masuda, Naoki Ishiguro, Kinji Ohno. PLoS One 2013
28
60

Skeletal overgrowth and deafness in mice lacking fibroblast growth factor receptor 3.
J S Colvin, B A Bohne, G W Harding, D G McEwen, D M Ornitz. Nat Genet 1996
687
17

Heterozygous mutations in natriuretic peptide receptor-B (NPR2) are associated with short stature.
Robert C Olney, Hülya Bükülmez, Cynthia F Bartels, Timothy C R Prickett, Eric A Espiner, Lincoln R Potter, Matthew L Warman. J Clin Endocrinol Metab 2006
115
16

Complementary antagonistic actions between C-type natriuretic peptide and the MAPK pathway through FGFR-3 in ATDC5 cells.
Ami Ozasa, Yasato Komatsu, Akihiro Yasoda, Masako Miura, Yoko Sakuma, Yuko Nakatsuru, Hiroshi Arai, Nobuyuki Itoh, Kazuwa Nakao. Bone 2005
43
37

Gly369Cys mutation in mouse FGFR3 causes achondroplasia by affecting both chondrogenesis and osteogenesis.
L Chen, R Adar, X Yang, E O Monsonego, C Li, P V Hauschka, A Yayon, C X Deng. J Clin Invest 1999
187
15

Thanatophoric dysplasia (types I and II) caused by distinct mutations in fibroblast growth factor receptor 3.
P L Tavormina, R Shiang, L M Thompson, Y Z Zhu, D J Wilkin, R S Lachman, W R Wilcox, D L Rimoin, D H Cohn, J J Wasmuth. Nat Genet 1995
476
15

Chronically elevated plasma C-type natriuretic peptide level stimulates skeletal growth in transgenic mice.
Takei Kake, Hidetomo Kitamura, Yuichiro Adachi, Tetsuro Yoshioka, Tomoyuki Watanabe, Hiroaki Matsushita, Toshihito Fujii, Eri Kondo, Takanori Tachibe, Yosuke Kawase,[...]. Am J Physiol Endocrinol Metab 2009
58
25

Tyrosine kinase inhibitor NVP-BGJ398 functionally improves FGFR3-related dwarfism in mouse model.
Davide Komla-Ebri, Emilie Dambroise, Ina Kramer, Catherine Benoist-Lasselin, Nabil Kaci, Cindy Le Gall, Ludovic Martin, Patricia Busca, Florent Barbault, Diana Graus-Porta,[...]. J Clin Invest 2016
37
40


A mouse model for achondroplasia produced by targeting fibroblast growth factor receptor 3.
Y Wang, M K Spatz, K Kannan, H Hayk, A Avivi, M Gorivodsky, M Pines, A Yayon, P Lonai, D Givol. Proc Natl Acad Sci U S A 1999
166
14


Achondroplasia: pathogenesis and implications for future treatment.
Melanie B Laederich, William A Horton. Curr Opin Pediatr 2010
41
34

Achondroplasia: Development, pathogenesis, and therapy.
David M Ornitz, Laurence Legeai-Mallet. Dev Dyn 2017
76
18

C-Type Natriuretic Peptide Analogue Therapy in Children with Achondroplasia.
Ravi Savarirayan, Melita Irving, Carlos A Bacino, Bret Bostwick, Joel Charrow, Valerie Cormier-Daire, Kim-Hanh Le Quan Sang, Patricia Dickson, Paul Harmatz, John Phillips,[...]. N Engl J Med 2019
49
28

A neonatal lethal mutation in FGFR3 uncouples proliferation and differentiation of growth plate chondrocytes in embryos.
T Iwata, L Chen, C Li, D A Ovchinnikov, R R Behringer, C A Francomano, C X Deng. Hum Mol Genet 2000
156
13

A novel FGFR3-binding peptide inhibits FGFR3 signaling and reverses the lethal phenotype of mice mimicking human thanatophoric dysplasia.
Min Jin, Ying Yu, Huabing Qi, Yangli Xie, Nan Su, Xiaofeng Wang, Qiaoyan Tan, Fengtao Luo, Ying Zhu, Quan Wang,[...]. Hum Mol Genet 2012
31
41

Activating Fgfr3 Y367C mutation causes hearing loss and inner ear defect in a mouse model of chondrodysplasia.
Stéphanie Pannier, Vincent Couloigner, Nadia Messaddeq, Monique Elmaleh-Bergès, Arnold Munnich, Raymond Romand, Laurence Legeai-Mallet. Biochim Biophys Acta 2009
38
34

A novel mutation in FGFR3 causes camptodactyly, tall stature, and hearing loss (CATSHL) syndrome.
Reha M Toydemir, Anna E Brassington, Pinar Bayrak-Toydemir, Patrycja A Krakowiak, Lynn B Jorde, Frank G Whitby, Nicola Longo, David H Viskochil, John C Carey, Michael J Bamshad. Am J Hum Genet 2006
85
15

A recurrent mutation in the tyrosine kinase domain of fibroblast growth factor receptor 3 causes hypochondroplasia.
G A Bellus, I McIntosh, E A Smith, A S Aylsworth, I Kaitila, W A Horton, G A Greenhaw, J T Hecht, C A Francomano. Nat Genet 1995
332
12


C-type natriuretic peptide regulates endochondral bone growth through p38 MAP kinase-dependent and -independent pathways.
Hanga Agoston, Sameena Khan, Claudine G James, J Ryan Gillespie, Rosa Serra, Lee-Anne Stanton, Frank Beier. BMC Dev Biol 2007
66
18

An activating mutation in the kinase homology domain of the natriuretic peptide receptor-2 causes extremely tall stature without skeletal deformities.
Sabine E Hannema, Hermine A van Duyvenvoorde, Thomas Premsler, Ruey-Bing Yang, Thomas D Mueller, Birgit Gassner, Heike Oberwinkler, Ferdinand Roelfsema, Gijs W E Santen, Timothy Prickett,[...]. J Clin Endocrinol Metab 2013
50
24

An activating Fgfr3 mutation affects trabecular bone formation via a paracrine mechanism during growth.
Emilie Mugniery, Romain Dacquin, Caroline Marty, Catherine Benoist-Lasselin, Marie-Christine de Vernejoul, Pierre Jurdic, Arnold Munnich, Valérie Geoffroy, Laurence Legeai-Mallet. Hum Mol Genet 2012
33
33

Coordination of chondrogenesis and osteogenesis by fibroblast growth factor 18.
Zhonghao Liu, Jingsong Xu, Jennifer S Colvin, David M Ornitz. Genes Dev 2002
335
11

Gain-of-function mutation in FGFR3 in mice leads to decreased bone mass by affecting both osteoblastogenesis and osteoclastogenesis.
Nan Su, Qidi Sun, Can Li, Xiumin Lu, Huabing Qi, Siyu Chen, Jing Yang, Xiaolan Du, Ling Zhao, Qifen He,[...]. Hum Mol Genet 2010
64
17

Nosology and classification of genetic skeletal disorders: 2010 revision.
Matthew L Warman, Valerie Cormier-Daire, Christine Hall, Deborah Krakow, Ralph Lachman, Martine LeMerrer, Geert Mortier, Stefan Mundlos, Gen Nishimura, David L Rimoin,[...]. Am J Med Genet A 2011
401
11



Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.